肝腎症候群の世界市場レポート 2025年

肝腎症候群市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で18億3,000万米ドルに成長します。予測期間中の成長は、肝疾患の有病率の増加、肝移植プログラムの拡大、罹患率の増加、直接腎障害の症例の増加、肝疾患の罹患率の増加などの要因によるものと考えられます。予測期間における主要動向としては、先端技術の採用、政府支援プログラムの強化、より優れた診断ツール、個別化医療の進展、腎臓学の進歩などが挙げられます。

肝疾患の有病率の増加は、肝腎症候群市場の成長を牽引すると予想されます。肝疾患には、肝炎、肝硬変、脂肪肝、肝がん、遺伝性疾患、自己免疫疾患など、肝機能を損なう疾患が含まれます。肥満、糖尿病、飲酒、ウイルス感染、食生活の乱れ、毒素への暴露などの要因が、肝疾患の罹患率上昇に寄与しています。肝硬変や急性肝不全などの病態は、肝臓が徐々に悪化するにつれて血行動態や腎臓の機能障害を引き起こし、肝腎症候群のリスクを高めています。例えば、2024年4月、OHID（Office for Health Improvement & Disparities）は、英国における肝疾患による入院患者数が、2022年の10万人当たり150.6人から、2023年には155.2人に増加したと報告しました。このような肝疾患の増加が肝腎症候群市場の成長を牽引しています。

研究開発投資の増加が肝腎症候群市場の成長をサポートすると予想されます。研究開発投資は、技術革新、製品開発、新技術の創造に不可欠です。こうした投資は、技術の進歩、市場競争、ヘルスケアのニーズ、新しいソリューションへの需要によって推進されます。肝腎症候群の場合、研究開発は治療法、診断ツール、治療アプローチを進歩させ、最終的には患者の転帰を改善しています。例えば、英国政府は2022年の研究開発費が10.5%増加し、2021年の140億ポンド（146億1,000万米ドル）から155億ポンド（161億8,000万米ドル）に達すると報告しています。この研究開発投資の増加が、肝腎症候群市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肝腎症候群 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の肝腎症候群市場：成長率分析
• 世界の肝腎症候群市場の実績：規模と成長、2019～2024年
• 世界の肝腎症候群市場の予測：規模と成長、2024～2029年、2034年
• 世界の肝腎症候群総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肝腎症候群市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 1型肝腎症候群
• 2型肝腎症候群
• その他
• 世界の肝腎症候群市場治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 肝臓移植
• テルリプレシン点滴
• アルブミン注入
• 血液透析
• 血管収縮薬
• 抗生物質療法
• 世界の肝腎症候群市場診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 全血球数
• 肝機能検査
• 尿検査と尿電解質
• その他
• 世界の肝腎症候群市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• その他
• 世界の肝腎症候群市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 在宅医療
• 専門クリニック
• その他
• 世界の肝腎症候群市場、1型肝腎症候群のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性肝腎症候群
• 急速進行性肝腎症候群
• 世界の肝腎症候群市場、2型肝腎症候群のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 慢性肝腎症候群
• 緩徐進行性肝腎症候群
• 世界の肝腎症候群市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肝硬変を伴う肝腎症候群
• 急性肝不全を伴う肝腎症候群
• アルコール性肝炎を伴う肝腎症候群

第7章 地域別・国別分析

• 世界の肝腎症候群市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の肝腎症候群市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肝腎症候群市場：競合情勢
• 肝腎症候群市場：企業プロファイル
  • Eli Lilly and Company
  • Becton Dickinson and Company
  • Teva Pharmaceutical Industries Ltd
  • Baxter International Inc.
  • Ferring Pharmaceuticals Ltd

第31章 その他の大手企業と革新的企業

• Mallinckrodt Pharmaceuticals
• Zentiva k.s
• Hybio Pharmaceutical Co. Ltd
• Cumberland Pharmaceuticals Inc.
• La Jolla Pharmaceutical Company
• Innoviva Specialty Therapeutics Inc
• SeaStar Medical
• New Medicon Pharma Lab
• Orphan Therapeutics LLC
• BioVie Inc.
• Noorik Biopharmaceuticals
• Ocelot Bio Inc.
• Ikaria Inc
• PharmaIN Corp
• ESP Pharma Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 肝腎症候群市場、2029年：新たな機会を提供する国
• 肝腎症候群市場、2029年：新たな機会を提供するセグメント
• 肝腎症候群市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Hepatorenal syndrome (HRS) is a serious complication that occurs in advanced liver disease, leading to functional kidney failure due to reduced blood flow to the kidneys, despite no structural damage. It results from splanchnic vasodilation, which triggers renal vasoconstriction and a reduction in glomerular filtration.

The primary types of hepatorenal syndrome include type 1, type 2, and other variations. Type 1 hepatorenal syndrome is a rapidly worsening kidney failure in individuals with severe liver disease, marked by a rapid decline in kidney function over a period of days to weeks. Treatment options for type 1 HRS include liver transplantation, terlipressin, albumin infusion, hemodialysis, vasoconstrictors, and antibiotics. To diagnose HRS, tests such as a complete blood count, liver function tests, urinalysis, and urine electrolytes are performed. It is available through hospital pharmacies, online pharmacies, retail pharmacies, and other outlets. The primary consumers include hospitals, home care services, specialty clinics, and other healthcare facilities.

The hepatorenal syndrome market research report is one of a series of new reports from The Business Research Company that provides hepatorenal syndrome market statistics, including the hepatorenal syndrome industry global market size, regional shares, competitors with the hepatorenal syndrome market share, detailed hepatorenal syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatorenal syndrome industry. This hepatorenal syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hepatorenal syndrome market size has grown strongly in recent years. It will grow from $1.29 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be credited to factors such as higher healthcare spending, an increase in hepatitis infections, government-driven initiatives, a growing prevalence of virally-induced liver diseases, and a rise in investments in research and development.

The hepatorenal syndrome market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be attributed to factors such as the growing prevalence of liver diseases, the expansion of liver transplant programs, an increase in disease rates, a rise in cases of direct kidney injury, and a higher incidence of liver diseases. Key trends in the forecast period include the adoption of advanced technologies, enhanced government support programs, better diagnostic tools, progress in personalized medicine, and advancements in nephrology.

The growing prevalence of liver diseases is expected to drive the growth of the hepatorenal syndrome market. Liver diseases include conditions such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases that impair liver function. Factors such as obesity, diabetes, alcohol consumption, viral infections, poor diet, and exposure to toxins contribute to the rising incidence of liver diseases. Conditions such as cirrhosis and acute liver failure increase the risk of hepatorenal syndrome by causing significant hemodynamic and kidney dysfunction as the liver progressively deteriorates. For example, in April 2024, the Office for Health Improvement & Disparities (OHID) reported that hospital admissions in the UK for liver disease had risen to 155.2 per 100,000 people in 2023, up from 150.6 per 100,000 in 2022. This increase in liver diseases is driving the growth of the hepatorenal syndrome market.

The rise in research and development investments is expected to support the growth of the hepatorenal syndrome market. R&D investments are crucial for innovation, product development, and the creation of new technologies. These investments are driven by technological progress, market competition, healthcare needs, and demand for new solutions. In the case of hepatorenal syndrome, R&D is advancing therapies, diagnostic tools, and treatment approaches, ultimately improving patient outcomes. For example, the UK government reported a 10.5% increase in R&D spending in 2022, reaching £15.5 billion (USD 16.18 billion), up from £14.0 billion (USD 14.61 billion) in 2021. This rise in R&D investment is fueling the growth of the hepatorenal syndrome market.

Companies in the hepatorenal syndrome market are also focusing on developing innovative therapies that target both liver and kidney dysfunction to improve patient outcomes. One such innovation is the cytopheretic device (Cytosorb), an extracorporeal blood purification therapy that reduces systemic inflammation and immune activation in critically ill patients, including those with hepatorenal syndrome. In October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, received FDA approval for its Selective Cytopheretic Device (SCD) to treat hepatorenal syndrome. This advanced therapy focuses on hyperinflammation, a key factor in kidney dysfunction in patients with acute-on-chronic liver failure. By modulating the immune response, SCD helps regulate abnormal immune responses, supporting kidney recovery and improving the chances of liver transplant eligibility. Its effectiveness in improving organ function has been demonstrated in preclinical and clinical studies across various conditions, including sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

Major players in the hepatorenal syndrome market are Eli Lilly and Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd, Baxter International Inc., Ferring Pharmaceuticals Ltd, Mallinckrodt Pharmaceuticals, Zentiva k.s, Hybio Pharmaceutical Co. Ltd, Cumberland Pharmaceuticals Inc., La Jolla Pharmaceutical Company, Innoviva Specialty Therapeutics Inc, SeaStar Medical, New Medicon Pharma Lab, Orphan Therapeutics LLC, BioVie Inc., Noorik Biopharmaceuticals, Ocelot Bio Inc., Ikaria Inc, PharmaIN Corp, and ESP Pharma Inc.

North America was the largest region in the hepatorenal syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatorenal syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatorenal syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatorenal syndrome market consists of revenues earned by entities by providing services such as medical management services, dialysis services, and liver transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatorenal syndrome market also includes sales of angiotensin, dialysis products, and continuous renal replacement therapy (CRRT) machines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatorenal Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatorenal syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatorenal syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatorenal syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1 Hepatorenal Syndrome; Type 2 Hepatorenal Syndrome; Other Types
• 2) By Treatment: Liver Transplantation; Terlipressin Infusion; Albumin Infusion; Hemodialysis; Vasoconstrictors; Antibiotic Therapy
• 3) By Diagnosis: Complete Blood Cell Count; Liver Function Tests; Urinalysis And Urine Electrolytes; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS; Rapidly Progressive Renal Failure
• 2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS; Slowly Progressive Renal Failure
• 3) By Other Types: HRS With Cirrhosis; HRS With Acute Liver Failure; HRS With Alcoholic Hepatitis
• Companies Mentioned: Eli Lilly and Company; Becton Dickinson and Company; Teva Pharmaceutical Industries Ltd; Baxter International Inc.; Ferring Pharmaceuticals Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatorenal Syndrome Market Characteristics

3. Hepatorenal Syndrome Market Trends And Strategies

4. Hepatorenal Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hepatorenal Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatorenal Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatorenal Syndrome Market Growth Rate Analysis
• 5.4. Global Hepatorenal Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatorenal Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatorenal Syndrome Total Addressable Market (TAM)

6. Hepatorenal Syndrome Market Segmentation

• 6.1. Global Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Hepatorenal Syndrome
• Type 2 Hepatorenal Syndrome
• Other Types
• 6.2. Global Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Transplantation
• Terlipressin Infusion
• Albumin Infusion
• Hemodialysis
• Vasoconstrictors
• Antibiotic Therapy
• 6.3. Global Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complete Blood Cell Count
• Liver Function Tests
• Urinalysis And Urine Electrolytes
• Other Diagnosis
• 6.4. Global Hepatorenal Syndrome Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.5. Global Hepatorenal Syndrome Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Hepatorenal Syndrome Market, Sub-Segmentation Of Type 1 Hepatorenal Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Kidney Injury-Associated HRS
• Rapidly Progressive Renal Failure
• 6.7. Global Hepatorenal Syndrome Market, Sub-Segmentation Of Type 2 Hepatorenal Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Kidney Dysfunction-Associated HRS
• Slowly Progressive Renal Failure
• 6.8. Global Hepatorenal Syndrome Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HRS With Cirrhosis
• HRS With Acute Liver Failure
• HRS With Alcoholic Hepatitis

7. Hepatorenal Syndrome Market Regional And Country Analysis

• 7.1. Global Hepatorenal Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatorenal Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatorenal Syndrome Market

• 8.1. Asia-Pacific Hepatorenal Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatorenal Syndrome Market

• 9.1. China Hepatorenal Syndrome Market Overview
• 9.2. China Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatorenal Syndrome Market

• 10.1. India Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatorenal Syndrome Market

• 11.1. Japan Hepatorenal Syndrome Market Overview
• 11.2. Japan Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatorenal Syndrome Market

• 12.1. Australia Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatorenal Syndrome Market

• 13.1. Indonesia Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatorenal Syndrome Market

• 14.1. South Korea Hepatorenal Syndrome Market Overview
• 14.2. South Korea Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatorenal Syndrome Market

• 15.1. Western Europe Hepatorenal Syndrome Market Overview
• 15.2. Western Europe Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatorenal Syndrome Market

• 16.1. UK Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatorenal Syndrome Market

• 17.1. Germany Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatorenal Syndrome Market

• 18.1. France Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatorenal Syndrome Market

• 19.1. Italy Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatorenal Syndrome Market

• 20.1. Spain Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatorenal Syndrome Market

• 21.1. Eastern Europe Hepatorenal Syndrome Market Overview
• 21.2. Eastern Europe Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatorenal Syndrome Market

• 22.1. Russia Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatorenal Syndrome Market

• 23.1. North America Hepatorenal Syndrome Market Overview
• 23.2. North America Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatorenal Syndrome Market

• 24.1. USA Hepatorenal Syndrome Market Overview
• 24.2. USA Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatorenal Syndrome Market

• 25.1. Canada Hepatorenal Syndrome Market Overview
• 25.2. Canada Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatorenal Syndrome Market

• 26.1. South America Hepatorenal Syndrome Market Overview
• 26.2. South America Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatorenal Syndrome Market

• 27.1. Brazil Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatorenal Syndrome Market

• 28.1. Middle East Hepatorenal Syndrome Market Overview
• 28.2. Middle East Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatorenal Syndrome Market

• 29.1. Africa Hepatorenal Syndrome Market Overview
• 29.2. Africa Hepatorenal Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatorenal Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatorenal Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatorenal Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Hepatorenal Syndrome Market Competitive Landscape
• 30.2. Hepatorenal Syndrome Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ferring Pharmaceuticals Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Hepatorenal Syndrome Market Other Major And Innovative Companies

• 31.1. Mallinckrodt Pharmaceuticals
• 31.2. Zentiva k.s
• 31.3. Hybio Pharmaceutical Co. Ltd
• 31.4. Cumberland Pharmaceuticals Inc.
• 31.5. La Jolla Pharmaceutical Company
• 31.6. Innoviva Specialty Therapeutics Inc
• 31.7. SeaStar Medical
• 31.8. New Medicon Pharma Lab
• 31.9. Orphan Therapeutics LLC
• 31.10. BioVie Inc.
• 31.11. Noorik Biopharmaceuticals
• 31.12. Ocelot Bio Inc.
• 31.13. Ikaria Inc
• 31.14. PharmaIN Corp
• 31.15. ESP Pharma Inc

32. Global Hepatorenal Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatorenal Syndrome Market

34. Recent Developments In The Hepatorenal Syndrome Market

35. Hepatorenal Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Hepatorenal Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatorenal Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatorenal Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer